Competitive LandscapeCompetitive landscape shows other companies also developing mast cell-driven disease therapies, posing potential challenges to Blueprint's market position.
Drug PerformanceBezuclastinib's performance in ISM did not differentiate itself from Ayvakit, while also exhibiting reductions in clinical effectiveness measures that were less effective compared to Ayvakit.
Financial PerformanceGavreto US sales have been disappointing, with annual revenue less than $30 million, following the termination of the Roche partnership and a 61% year over year decline in 4Q23 collaboration revenue.